Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US
Last year, a team of researchers at the Case Western Reserve University School of Medicine studied 1.6 million patients with type 2 diabetes and found that those on GLP-1 drugs had significant risk reduction of ten cancers: esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, and pancreatic cancer, as well as meningioma and multiple myeloma
As more research emerges, GLP-1 medications may become a powerful adjunct therapy in rheumatologysupporting traditional treatments and improving long-term outcomes
Some telehealth companies like Ro and Hims hire third-party companies to test the compounded medications for quality and purity, but not all of them do
It also contributes to better balance and bone density, reducing injury and osteoporosis risk